Crossmark

Early kinetics of serum amyloid A predict clinical benefit to first-line chemoimmunotherapy and immunotherapy in advanced non-small cell lung cancer: a retrospective analysis

Crossref DOI link: https://doi.org/10.1186/s40364-025-00791-1

Published Online: 2025-05-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Du, Wei

Zhan, Jianhua

Wu, Kai

Wang, Yanming

Zhang, Li

Hong, Shaodong
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82172713)

Natural Science Foundation of Guangdong Province (2023B1515020008)

National Major Science and Technology Projects of China (2024ZD0520200, 2024ZD0520205)
License Information

Text and Data Mining valid from 2025-05-24

Version of Record valid from 2025-05-24
More Information

Article History

Received: 26 February 2025

Accepted: 19 May 2025

First Online: 24 May 2025

Declarations

:

: This study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (approved number: B2020-402–01). Individual consent for this retrospective analysis was waived. For protection of the patient’s personal data, only anonymized data have been used for the analyses of this study.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below